Today: 5 February 2026
Subscribe
Browse Category

Biotech News News 30 December 2025 - 4 January 2026

Spyre Therapeutics stock slid 6.6% into the weekend — here’s what matters before Monday’s open

Spyre Therapeutics stock slid 6.6% into the weekend — here’s what matters before Monday’s open

NEW YORK, Jan 4, 2026, 11:15 ET — Market closed Spyre Therapeutics shares fell 6.6% to $30.58 on Friday, then ticked up about 2% in after-hours trading, as U.S. markets headed into the weekend. Yahoo Finance With markets shut on Sunday, the Friday move leaves Spyre starting the new week with momentum tilted lower — a reminder that development-stage biotech…
4 January 2026
·····
Kymera Therapeutics (KYMR) stock drops 6.6% to start 2026 as insider sale filing stays in focus

Kymera Therapeutics (KYMR) stock drops 6.6% to start 2026 as insider sale filing stays in focus

NEW YORK, Jan 3, 2026, 20:43 ET — Market closed Kymera Therapeutics shares slid on Friday, ending down 6.6% at $72.76 as the biotech underperformed its sector even as the broader market started 2026 on a mixed note. The move matters because Kymera has been a high-beta biotech name since a sharp rally in December on early trial data for…
4 January 2026
····
Spyre Therapeutics stock slides 6.6% after New Year session; $30 level and 2026 trial data in focus

Spyre Therapeutics stock slides 6.6% after New Year session; $30 level and 2026 trial data in focus

NEW YORK, January 3, 2026, 20:15 ET — Market closed Spyre Therapeutics, Inc. shares fell 6.6% on Friday to $30.58, finishing the first U.S. trading day of 2026 near the lower end of the session’s $30.11-$33.31 range. The stock remains below its 52-week high of $34.49 after trading about 889,000 shares, while biotech benchmarks were little changed. The slide stands…
4 January 2026
·····
Kymera Therapeutics stock slides nearly 7% after CEO share-sale filing — what KYMR investors watch next

Kymera Therapeutics stock slides nearly 7% after CEO share-sale filing — what KYMR investors watch next

NEW YORK, Jan 2, 2026, 15:39 ET — Regular session Kymera Therapeutics Inc (KYMR.O) shares fell nearly 7% on Friday afternoon after a regulatory filing disclosed a year-end sale by Chief Executive Nello Mainolfi. Kymera was down 6.9% at $72.42, after earlier touching $72.18. The move matters because Kymera has become a high-sensitivity biotech name, with investor expectations tied closely…
2 January 2026
····
Arcutis Biotherapeutics stock today: ARQT ends 2025 up 3.4% as traders eye FDA, earnings dates

Arcutis Biotherapeutics stock today: ARQT ends 2025 up 3.4% as traders eye FDA, earnings dates

NEW YORK, January 1, 2026, 21:21 ET — Market closed With U.S. markets closed for New Year’s Day, shares of Arcutis Biotherapeutics Inc (ARQT) last closed up 3.42% at $29.04 in the final trading session of 2025. The stock ranged from $28.08 to $29.67 on volume of about 1.87 million shares. ARQT is up about 99% over the past year…
2 January 2026
····
INBS stock today: Intelligent Bio Solutions swings after $10 million raise follows new manufacturing deal

INBS stock today: Intelligent Bio Solutions swings after $10 million raise follows new manufacturing deal

NEW YORK, January 1, 2026, 11:36 ET — Market closed Intelligent Bio Solutions Inc. shares swung sharply into year-end after the medical-device maker said it would raise about $10 million in a private placement, prompting a drop in after-hours trading following a session in which the stock more than doubled. GlobeNewswire With U.S. stock markets closed on Thursday for New…
1 January 2026
·····
Corcept Therapeutics (CORT) stock sinks after FDA rebuff; relacorilant outlook resets

Corcept Therapeutics (CORT) stock sinks after FDA rebuff; relacorilant outlook resets

NEW YORK, January 1, 2026, 10:45 ET — Market closed. Corcept Therapeutics Inc (CORT) shares last ended Wednesday down 50.4% at $34.80 after the company said U.S. regulators were not ready to approve its drug relacorilant for a form of high blood pressure linked to hypercortisolism. U.S. stock markets are shut on Thursday for New Year’s Day. HCPLive The selloff…
1 January 2026
·····
Disc Medicine (IRON) stock today: year-end rally keeps January FDA decision in focus

Disc Medicine (IRON) stock today: year-end rally keeps January FDA decision in focus

NEW YORK, January 1, 2026, 10:07 ET — Market closed Disc Medicine, Inc. shares rose 3.3% to $79.41 in the last U.S. trading session of 2025, before Wall Street shut on Thursday for the New Year’s Day holiday. Investors are focused on a U.S. Food and Drug Administration decision expected by the end of January on Disc’s lead drug candidate…
1 January 2026
·····
Arcutis Biotherapeutics stock pops today as ARQT bucks biotech dip into year-end trade

Arcutis Biotherapeutics stock pops today as ARQT bucks biotech dip into year-end trade

NEW YORK, December 31, 2025, 10:33 ET — Regular session Shares of Arcutis Biotherapeutics Inc rose 3.8% to $29.16 by 10:33 a.m. ET on Wednesday, extending gains in the final U.S. trading session of 2025. The Nasdaq-listed dermatology drugmaker traded between $28.08 and $29.19, with about 181,000 shares changing hands. The move puts ARQT within striking distance of $30 and…
31 December 2025
·····
SRRK stock drops 3% today: What’s driving Scholar Rock shares as FDA reinspection nears

SRRK stock drops 3% today: What’s driving Scholar Rock shares as FDA reinspection nears

NEW YORK, December 30, 2025, 15:25 ET — Regular session Scholar Rock Holding Corp (SRRK) slid 3.2% to $43.76 in afternoon trading on Tuesday after opening at $45.18. The stock traded between $45.95 and $43.74. The move matters because Scholar Rock’s near-term valuation still hinges on regulatory timing for apitegromab, its lead drug candidate. he company said in an October…
30 December 2025
·····
Arcutis Biotherapeutics stock slides today as biotech pulls back, ARQT down nearly 3%

Arcutis Biotherapeutics stock slides today as biotech pulls back, ARQT down nearly 3%

NEW YORK, December 30, 2025, 14:45 ET — Regular session Arcutis Biotherapeutics shares fell 2.9% to $27.74 in afternoon trading on Tuesday, after moving between $27.72 and $28.65. Volume was about 0.6 million shares. The drop outpaced broader biotech gauges, with the SPDR S&P Biotech ETF down about 1.5% and the iShares Nasdaq Biotechnology ETF off about 1.1%. That matters…
30 December 2025
·····
Vera Therapeutics stock drops 3% today as biotech slips into year-end trading

Vera Therapeutics stock drops 3% today as biotech slips into year-end trading

NEW YORK, December 30, 2025, 2:26 PM ET — Regular session Vera Therapeutics, Inc. shares slid 3.4% to $50.45 in afternoon trading on Tuesday, giving back some recent gains as biotech stocks softened late in the year. The move matters now because Vera has become a bellwether “event-driven” biotech name, where day-to-day trading can swing sharply as investors calibrate risk…
30 December 2025
······
1 … 3 4 5 6 7 … 12

Stock Market Today

  • Software Stocks Falter as Google Boosts AI Spend; Layoffs Surge Ahead of Delayed Jobs Report
    February 5, 2026, 9:21 AM EST. Software stocks face renewed pressure amid skepticism about the sector's trajectory as artificial intelligence expands in enterprise. Alphabet, Google's parent, surpassed Q4 expectations but warned of capital expenditures potentially doubling in 2026 to support AI infrastructure, triggering a 4% drop in premarket shares. Meanwhile, AI suppliers like Broadcom saw gains. Labor market signals dim with delayed U.S. job reports, recent private sector hiring falling short, and January layoffs surging by over 200% from December, the highest for the month since 2009. Oil prices climbed 1.5% in Asia over fears of a U.S. strike on Iran potentially disrupting supply.
Go toTop